Humacyte’s (HUMA) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report released on Friday,Benzinga reports. The brokerage currently has a $25.00 price objective on the stock.

Other research analysts also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective (up from $12.00) on shares of Humacyte in a report on Friday, December 20th. Benchmark reaffirmed a “buy” rating on shares of Humacyte in a report on Thursday, February 27th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $13.71.

Humacyte Stock Up 4.4 %

Humacyte stock opened at $3.09 on Friday. Humacyte has a twelve month low of $2.81 and a twelve month high of $9.97. The firm has a 50 day moving average price of $4.18 and a 200-day moving average price of $4.85. The company has a market capitalization of $388.90 million, a P/E ratio of -2.31 and a beta of 1.36.

Institutional Investors Weigh In On Humacyte

A number of large investors have recently added to or reduced their stakes in HUMA. Woodline Partners LP grew its holdings in Humacyte by 235.7% in the 4th quarter. Woodline Partners LP now owns 2,848,802 shares of the company’s stock worth $14,386,000 after acquiring an additional 2,000,268 shares during the last quarter. State Street Corp grew its holdings in Humacyte by 66.1% in the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company’s stock worth $25,917,000 after acquiring an additional 1,895,529 shares during the last quarter. CenterBook Partners LP bought a new stake in shares of Humacyte during the 4th quarter valued at about $6,463,000. Brevan Howard Capital Management LP boosted its stake in shares of Humacyte by 2,795.1% during the 4th quarter. Brevan Howard Capital Management LP now owns 876,340 shares of the company’s stock valued at $4,426,000 after purchasing an additional 846,070 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Humacyte by 10.8% during the 4th quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company’s stock valued at $28,294,000 after purchasing an additional 543,995 shares in the last quarter. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.